Introduction {#S1}
============

Chronic Neuropathic Pain {#S1.SS1}
------------------------

An epidemiological survey has clearly revealed that nearly 19% of adult Europeans suffered from chronic pain of moderate to severe intensity, which not only seriously affected the physical and mental quality of their social and working lives but also represents a significant public health issue that can be costly to the healthcare system ([@B83]). Among all the different types of chronic pain, neuropathic pain is relatively common, but difficult to treat and manage ([@B4], [@B5]). Moreover, neuropathic pain occurs in approximately 7--10% of the general population; therefore, neuropathic pain remains one of the most serious public health problems ([@B96]). Traditionally, the International Association for the Study of Pain (IASP) proposed a clinical description for neuropathic pain, which is defined as "pain initiated or caused by a primary lesion or dysfunction in the nervous system" ([@B87]). However, this definition is broad, covering over 100 conditions, and has been controversial in recent years ([@B65]; [@B62]). The main reason is that many scholars believe that the meaning of the term "dysfunction" is still relatively vague ([@B5]). Furthermore, it does not distinguish well between neuropathic pain and nociceptive pain ([@B98]). Recently, a new precise definition of neuropathic pain has been put forward to avoid the above shortcomings, and to further beneficially support clinical and research purposes ([@B50]; [@B95]). The revised definition is that "pain arose as a direct consequence of a lesion or disease affecting the somatosensory system," which definitely indicates that the peripheral or central somatosensory system must be involved ([@B87]; [@B95]). According to the underlying etiology and the anatomical location of the specific lesion, clinical neuropathic pain is haply divided into four main types, namely, painful peripheral neuropathies, central pain syndromes, complex painful neuropathic disorders, and mixed-pain syndromes ([@B5]; [@B68]). Painful peripheral neuropathies are caused by ischemic, traumatic, inflammatory, infectious, metabolic, or compressive damage to the peripheral nervous system (PNS), such as polyneuritis, phantom limb pain, diabetic peripheral neuralgia, post-herpetic neuralgia, etc. ([@B8]; [@B102]). Central pain syndromes result from the dysfunction of or damage to the central nervous system (CNS) pain conduction pathway, mainly involving cerebrovascular disease, spinal cord trauma, etc. ([@B71]). Complex painful neuropathic disorders are also called "complex regional pain syndromes (CRPS)," which may result in trauma and affect the limbs ([@B6]; [@B11]). In addition, mixed-pain syndromes are the combination of nociceptive and neuropathic pain ([@B5]; [@B72]).

Generally, patients with neuropathic pain may show distinct negative and positive sensory symptoms or signs in the nerve distribution area ([@B4]). Firstly, the negative sensory symptoms predominately contain hypoesthesia, pallhypoesthesia, hypoalgesia, thermohypoesthesia, etc. ([@B4]; [@B88]). Secondly, the positive sensory symptoms primarily include paresthesia, paroxysmal pain, superficial pain, and evoked pain. This would stimulate induced hypersensitivity and pain, such as light-pressure, gentle static pressure, and sharp pinprick ([@B4]; [@B91]). However, in a clinical setting, patients often were diagnosed as hyperesthesias that are mainly referred to as paresthesia and hyperalgesia ([@B115]). The two types of hyperesthesia need to be clearly distinguished. Paresthesia (also known as mechanodynamic painful paresthesia) is defined as the non-noxious stimuli (e.g., light touch, warm, cool), and normally would not cause painful sensation in the normal nerve areas, but it could cause strongly painful sensation in the damaged nerve areas ([@B5]; [@B3]). Nevertheless, hyperalgesia is defined as an increased pain sensitivity or painful summation to mildly noxious stimuli ([@B5]; [@B40]). To date, pharmacotherapy is the main therapeutic strategy in neuropathic pain patients. However, these drugs and agents lack specificity and efficiency, and could reduce the pain to a more tolerable level ([@B93]; [@B31]). Thus, it is urgently needed to further explore the potential molecular mechanisms of the neuropathic pain development, which may provide a rational solution for clinical treatment and novel drug discovery in neuropathic pain.

Long Non-coding RNAs (lncRNAs) {#S1.SS2}
------------------------------

With the development of larger-scale sequencing techniques and bioinformatics methods, the Encyclopedia of DNA Elements (ENCODE) project, the most comprehensive effort yet for surveying transcription in human cells, has clearly uncovered that only approximately 2% of the whole human genome encodes functional protein-coding genes, while the remaining genome is actively transcribed into a diversity of RNAs that were defined as non-coding RNAs (ncRNAs) and were previously believed to be non-functional "dark matter" ([@B74]). However, an accumulating body of evidence in recent years reported that, similar to protein-coding genes, ncRNAs are also involved in a wide variety of biological processes, such as cell proliferation, cellular structure integrity, cellular development, differentiation, stem cell pluripotency, signaling transductions, genomic imprinting, the maintenance of genomic integrity, reprogramming, heat shock response, etc. ([@B67]; [@B90]). Therefore, it was no surprise that abnormal expression profiles of ncRNAs were implicated in the initiation, development, and progression processes of many human diseases, including cardiovascular syndromes, diabetes, autoimmune diseases, nervous system disorders, cancers, and so on ([@B36]). However, among all classifications of ncRNAs, lncRNAs, a heterogeneous group of transcripts that are greater than 200 nucleotides (nt) in length, account for more than 80% of ncRNAs ([@B38]). Because lncRNAs occupy the largest class of ncRNAs and represent the most prevalent and functionally diverse class of ncRNAs, they attract interest in the scientific community in the past decades ([@B85]).

Since Brannan and his colleagues reported the first lncRNA H19 in 1990, thousands of lncRNAs have been identified in a large diversity of species, including mammalian animals, plants, yeast, prokaryotes, and even viruses, by a large number of scientists ([@B38]). It is reported that the lncRNA is bidirectional transcribed, depending on their proximity to the nearest protein-coding transcripts. It can be grouped into five main categories: sense lncRNAs (lncRNAs initiate inside or 5' of a protein-coding gene, then are transcribed in the same direction as protein-coding genes, and ultimately overlap at least one protein-coding exon), antisense lncRNAs (lncRNAs initiate inside or 3' of a protein-coding gene, then are transcribed in the opposite direction of protein-coding genes, and ultimately overlap at least one protein-coding exon), bidirectional lncRNAs (the expression of the lncRNA and its neighboring protein-coding genes on the opposite strand is initiated in close genomic proximity), intronic lncRNAs (the entire sequence of the lncRNA falls within the intron of a protein-coding gene), and intergenic lncRNAs (also termed large intervening ncRNAs or lincRNAs, in which the entire sequence of the lncRNA falls between two protein-coding genes as a distinct unit) ([Figure 1A](#F1){ref-type="fig"}; [@B61]; [@B92]). In addition, an increasing number of studies have found that lncRNAs play versatile roles in many aspects of gene regulation through four functional mechanisms: signaling and acting as a decoy, guide, and scaffolding molecule ([Figure 1B](#F1){ref-type="fig"}; [@B1]; [@B17]). First, as a signaling molecule, lncRNAs are usually transcribed in a specific time and space, and their transcripts can integrate developmental cues, interpret cell status, or respond to multiple stimuli and further regulate the expression of other genes. Therefore, lncRNAs are seen as an important marker in a biological event ([@B100]). Second, as a decoy molecule, lncRNA can block the binding of transcriptional repressors to their homologous target gene promoters, as well as protein molecules, chromatin modifications, etc., and thereby lncRNAs could ultimately inhibit their functions ([@B60]). Third, as a guide molecule, lncRNAs are able to directly bind to the protein molecules and then guide the protein complexes containing the above-described protein-bound molecules to be precisely localized on a specific target ([@B100]). On the other hand, lncRNA can also recruit more transcription-related and epigenetic-related regulatory factors widely and further guide their localizations ([@B28]). Finally, as a scaffold molecule, lncRNAs have many different structural domains that can combine different effector molecules to achieve the assembly of macromolecules at the same time. In fact, lncRNA is a complex assembly center platform, which can recruit many related molecules together to further activate or inhibit the expression of other genes ([@B9]; [@B60]). It is extremely important for the transmission of many biological signals, intermolecular interactions, and the precise regulation of the specificity and dynamics of the signal itself ([@B100]; [@B63]). Hence, based on the multiple functions of lncRNAs, researchers have gradually shifted their focus of research over the last few decades from previous studies on protein-coding gene-induced diseases to studies on lncRNA-induced diseases ([@B63]; [@B17]).

![The classification and functional mechanisms of lncRNAs. **(A)** Classification of lncRNAs according to the relative proximity to the nearest protein-coding transcripts; **(B)** Functions of lncRNAs in regulating target genes.](fnins-13-01097-g001){#F1}

The Roles of lncRNAs in the Nervous System and Its Related Diseases {#S2}
===================================================================

The human nervous system is the most highly evolved and sophisticated biological system that plays a leading role in the regulation of physiological and functional activities in the body ([@B32]; [@B34]). Generally, the functions and physiological processes of different organs and systems in the human body are not carried out in isolation, but they are closely connected, interacting and cooperating under the direct or indirect control of the nervous system, which makes the human body become a complete and unified organism to achieve and maintain normal life activities when the human body encounters interoceptive and environmental stimuli ([@B33]; [@B47]). It is well-known that the human nervous system is mainly composed of nerve tissues that contain two basic types of cells, neurons and glial cells, and is divided into two major parts, the CNS and the PNS ([@B24]; [@B114]). The CNS, containing the brain and the spinal cord, is where we receive sensory information, generate thoughts and emotions, and store memories ([@B45]; [@B21]). The perfect presentation of CNS and PNS functions predominately depends on the dynamic neural networks organized by neuronal and glial cells ([@B29]). However, the development of these cells requires a precise spatiotemporal regulation of stem/progenitor cell proliferation and differentiation at various levels, such as epigenetic, transcriptional, or post-transcriptional processes, and then forms appropriate connections with each other ([@B76]). In recent years, emerging data have reported that an increasing number of lncRNAs were found to play vital roles in mediating the developmental complexity of the nervous system, and these abundant lncRNAs are precisely, dynamically, and specifically expressed in the brain via temporal and spatial expression patterns ([@B77]). In fact, it is not difficult to understand that the development of the nervous system is actually a complex neural network formed by the tight gene regulation of its constituent cells ([@B24]). Nevertheless, based on the explanation of the functions of lncRNAs in the above, it can be known that the regulatory mechanisms of lncRNAs may participate in the entire process of nervous system development ([@B105]). Therefore, not surprisingly, the dysregulation of or mutations in lncRNA gene loci might directly affect nervous system development, function, maintenance, and differentiation and be intimately associated with the molecular pathophysiology of a broad array of the most devastating neurological diseases, such as glioma, neuropathic pain, autism spectrum disorder (ASD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Asperger's syndrome, schizophrenia, developmental delay, amyotrophic lateral sclerosis (ALS), depression, autism, and others ([@B84]; [@B99]).

First, we explored the roles of lncRNA in neuronal development ([@B105]; [@B79]). Several lines of evidence have demonstrated that the profiles of lncRNA expression present a dynamic change during the process of neuronal development ([@B80]). For example, Mercer et al. discovered that 1328 lncRNAs were identified in the mouse, whereas among these lncRNAs, 849 lncRNAs were located in the mouse brain with 623 lncRNAs exhibiting selective profiles for specific regions (e.g., olfactory bulb, hippocampus, cortex, or cerebellum), cell types (e.g., neurons, glia cells), and subcellular compartments (e.g., dendrite, axon, Nissl body, soma, etc.), which suggested that these lncRNAs might be involved in regulating specific processes through cell- type-, subcellular- compartment-, and developmental-stage-specific manners ([@B13]). Amaral et al. revealed that the lncRNA Sox2OT was expressed in regions of constitutive adult neurogenesis and mediated the expression of the Sox2 gene, which is a key transcription factor (TF) that is responsible for the neural induction and maintenance of neural stem and progenitor cells, indicating that the lncRNA Sox2OT might participate in neural cell fate decisions ([@B2]). Other studies related to lncRNAs in neuronal development are shown in [Table 1](#T1){ref-type="table"}. Throughout the study of these lncRNAs in neurodevelopment, it is known that the methods of exploring the physiological functions of lncRNAs are basically the same. Researchers often use qRT-PCR to detect changes in the expression of lncRNAs in blood samples from patients with neurological diseases, in cell model samples, or in animal model samples. Moreover, a dual-luciferase reporter assay was applied to verify the target interaction between lncRNAs and their downstream target genes. In addition, CCK8, colony formation assay, and flow cytometry were utilized to assess the influences of lncRNA on neuronal development.

###### 

lncRNAs' roles in neuronal development.

  **lncRNAs**                                                                                               **Location**     **Expression**   **Samples**                                       **Roles of lncRNAs in**                                                                                          **References**
  --------------------------------------------------------------------------------------------------------- ---------------- ---------------- ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------
  BC1 (Brain cytoplasmic RNA 1)                                                                             Chromosome 7     Down-regulated   Mice                                              Changes behavioral phenotypes including reduced exploration and increased anxiety                                [@B51]
  BRN1B (also named Pantr2, POU domain, class 3, transcription factor 3 adjacent non-coding transcript 2)   Chromosome 1     Down-regulated   Developing mouse pups                             Controls differentiation of delaminating neural progenitor cells                                                 [@B86]
  DALI (DNMT1 associated lincRNA)                                                                           Chromosome 1     Up-regulated     Neuroblastoma cells                               Drives the expression of an essential neuronal differentiation gene expression program                           [@B14]
  EVF2 (also termed DLX6-AS1, DLX6 antisense RNA 1)                                                         Chromosome 7     Down-regulated   Mice                                              Disrupts the excitatory to inhibitory neuron balance in the post-natal hippocampus and dentate gyrus             [@B10]
  GOMAFU (also called MIAT, myocardial infarction associated transcript)                                    Chromosome 5     Down-regulated   Mice                                              Regulates splicing of several neuronal genes and increases amacrine cell and Muller glia differentiation         [@B81]; [@B12]
  KCNA2-AS (Potassium voltage-gated channel subfamily A member 2 antisense RNA)                             --               Up-regulated     The PNS of rats                                   Implicate in the control of neuronal plasticity                                                                  [@B12]
  Nkx2.2AS (NKX2-2 antisense RNA)                                                                           20p11.22         Up-regulated     Neural stem cells (NSCs)                          Enhances oligodendrocytic differentiation                                                                        [@B94]
  NTAB (Nitrilotriacetate monooxygenase component B)                                                        --               Up-regulated     Developing and adult rat brain                    Involve regulation of RNA transport or translation in neuronal processes                                         [@B23]
  PAUPAR (PAX6 upstream antisense RNA)                                                                      11p13            Up-regulated     Neuroblastoma cells                               Regulates a transcriptional program that influences the cell-cycle profile and differentiation                   [@B97]
  PNKY (A neural-specific lncRNA)                                                                           Chromosome 6     Down-regulated   Dividing NSCs of mouse and human brain            Controls the balance between self-renewal and neuronal differentiation                                           [@B78]
  RMST (Rhabdomyosarcoma 2 associated transcript)                                                           12q23.1; 12q21   Up-regulated     Human brain, Human embryonic stem cells (hESCs)   Required for neural differentiation                                                                              [@B66]
  SIX3OS (SIX homeobox 3, opposite strand 1)                                                                Chromosome 17    Up-regulated     Mice                                              Controls the specification of photoreceptors, bipolar cells, and Muller glia and regulates retinal development   [@B82]
  TUG1 (Taurine up-regulated 1)                                                                             Chromosome 11    Up-regulated     Mice                                              Involved in retinal development                                                                                  [@B111]
  TUNA (Tcl1 upstream neuron-associated lincRNA)                                                            Chromosome 12    Up-regulated     Mice embryonic stem cells (mESCs)                 Controls pluripotency and neural lineage commitment                                                              [@B57]

Second, we continue to investigate the effects of lncRNAs on neurological diseases ([@B84]). For instance, over-expressed lncRNA HOXA transcript antisense RNA, myeloid-specific 1 (HOTAIRM1), facilitates tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme ([@B54]). LncRNA small nucleolar RNA host gene 12 (SNHG12) accelerates angiogenesis following ischemic stroke via a miR-150/VEGF pathway, which further clarifies the mechanism of angiogenesis after ischemic stroke and provides a target for the treatment of this disease ([@B112]). The imbalance of lncRNA AK127244 might have a particular influence on language development and behavior or mood in neuropsychiatric disorders ([@B20]). Nuclear factor-k-gene binding (NF-kB) interacting lncRNA (NKILA) promotes the endoplasmic reticulum stress/autophagy pathway and suppresses the NF-kB pathway after intracerebral hemorrhage ([@B41]). Other studies linked to lncRNAs in neuronal-associated disorders are detailed in [Table 2](#T2){ref-type="table"}.

###### 

lncRNAs' roles in neuronal associated disorders.

  **lncRNAs**                                                 **Location**   **Expression**   **Samples**                                    **Neuronal associated disorders**   **Roles of lncRNAs in neuronal associated disorders**                                                                                                                                                           **References**
  ----------------------------------------------------------- -------------- ---------------- ---------------------------------------------- ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  ANRIL (Antisense non-coding RNA in the INK4 locus)          9p21.3         Up-regulated     Patients                                       Intracranial aneurysms              ANRIL may become a molecular marker of intracranial aneurysms in the future                                                                                                                                     [@B15]
  AK042766                                                    --             Up-regulated     Mice                                           Restless Legs Syndrome (RLS)        AK042766 may regulate the expression of the Meis1 gene during the pathogenesis of Restless Legs Syndrome (RLS)                                                                                                  [@B73]
  BC200 (also termed BCYRN1, brain cytoplasmic RNA 1)         2p21           Up-regulated     Patients                                       AD                                  BC200 is involved in the synaptic and neural network dysfunction that is found in both early and later stages of AD                                                                                             [@B53]
  BACE1-AS (Beta-secretase 1 antisense RNA)                   11q23.3        Down-regulated   Patients, mice                                 AD                                  BACE1-AS drives overproduction of toxic AB-42 peptides, which then feedback to further induce BACE1-AS overexpression, accelerating amyloid accumulation and finally leading to the generation of AD            [@B22]
  DISC2 (Disrupted in schizophrenia 2)                        1q42.2         Down-regulated   Patients                                       Neuropsychiatric disorders          DISC2 has been implicated in the development of neuropsychiatric disorders, such as autism spectrum disorder                                                                                                    [@B104]
  H19 (Human homolog 19)                                      11p15.5        Up-regulated     Patients, human glioma cell lines              CNS tumors                          H19 deregulation may be relevant for CNS tumors, such as glioma                                                                                                                                                 [@B64]
  GOMAFU                                                      Chromosome 5   Down-regulated   Mice, human pluripotent-cell-derived neurons   Schizophrenia                       GOMAFU may be involved in driving this aberrant splicing of DISC1 and ERRB4 in schizophrenia                                                                                                                    [@B7]; [@B12]
  KCNA2-AS                                                    --             Up-regulated     Rat                                            Neuropathic pain                    KCNA2-AS appears to be a key driver of neuropathic pain symptoms                                                                                                                                                [@B12]; [@B56]
  M21981                                                      --             Up-regulated     Mice                                           MS                                  M21981 are involved in abnormal CD8+ T-cell differentiation and activation in the pathophysiology of MS                                                                                                         [@B30]; [@B75]
  MEG3 (Maternally expressed gene 3)                          14q32.2        Up-regulated     Glioma cells U251                              Glioma                              MEG3 inhibits proliferation and migration but induces autophagy by regulation of Sirt7 and PI3K/AKT/mTOR pathway in glioma cells                                                                                [@B108]
  MSNP1AS (Moesin pseudogene 1 antisense RNA)                 5p14.1         Up-regulated     Patients                                       ASD                                 MSNP1AS may regulate MSN protein by binding to and stabilizing MSN mRNA, and that this mechanism may causally connect SNP variants in the MSNP1AS locus to ASD pathogenesis                                     [@B46]; [@B18]
  REST/CoREST-regulated lncRNAs                               --             Down-regulated   Patients                                       HD                                  The potential disruption of REST-regulated lncRNA expression in HD may lead to additional disturbances in lncRNA-mediated chromatin and transcriptional regulatory processes through a feed-forward mechanism   [@B44]
  UCH1LAS (Ubiquitin C-terminal hydrolase L1 antisense RNA)   4p14           Up-regulated     Patients                                       PD                                  UCH1LAS involves in regulating pathways related to the development of PD                                                                                                                                        [@B48]
  XCI (X chromosome inactivation)                             Chromosome X   Up-regulated     Patients                                       CNS tumors                          Perturbations in XCI expression are associated with CNS tumors                                                                                                                                                  [@B75]

The Abnormal Expression of lncRNAs and Their Potential Clinical Applications in Chronic Neuropathic Pain {#S3}
========================================================================================================

Chronic neuropathic pain generally resulting from injury to or disease of the nervous system has always been very difficult in clinical treatment, mainly because almost all patients with chronic neuropathic pain are notoriously resistant to the actions of currently available analgesics, such as non-steroidal anti-inflammatory drugs and opioids, which could exert effective therapeutic roles in nociceptive pain ([@B37]). Pharmacological (e.g., tricyclic antidepressants, anticonvulsants, selective serotonin norepinephrine reuptake inhibitors, and topical lidocaine), non-pharmacological (e.g., behavioral, cognitive, integrative, and physical approaches), and interventional (e.g., neuroablative and neuromodulation techniques) therapies are currently used in the treatment of chronic neuropathic pain. These treatments cannot completely control the symptoms of patients with chronic neuropathic pain, which may be associated with the diversity of pathophysiological situations, different pain etiologies, genetic predispositions, etc. ([@B26]). Thus, chronic neuropathic pain remains a distressing and debilitating disease, there is still no panacea for the treatment of chronic neuropathic pain in the clinic, and it is imperative to further develop chronic neuropathic pain drugs ([@B39]; [@B109]). In recent years, a large number of studies have revealed that many prominent and well-characterized mechanisms were observed in chronic neuropathic pain, including (1) ongoing ectopic activity in peripheral nerves, which resulted in excitation--inhibition imbalance; (2) the aberrant production and release of anti-inflammatory or proinflammatory cytokines at the site of injury, which triggers peripheral sensitization or central sensitization; (3) the impairment of endogenous inhibitory mechanisms of nociception sensitivity-induced microglial sensitivity after nerve injury, which enhanced the post-injury pain sensitivity; and (4) microglial activation after nerve injury, which contributed to the pathogenesis of pain hypersensitivity ([@B26]). Therefore, in the full understanding of the pathogenesis of chronic neuropathic pain, we can develop corresponding new therapeutic drugs for chronic neuropathic pain patients according to their relevant mechanisms ([@B27]; [@B98]). Furthermore, most extensive evidence has definitely pointed out that there were many dysregulated lncRNAs expressed in damaged nerves, primary sensory dorsal root ganglion neurons, spinal cord dorsal roots, the prefrontal cortex, the post-synaptic dorsal horn, and even in higher-order neurons up to the cortical level after peripheral nerve injury; therefore, it was speculated that these dysregulated lncRNAs might be involved in the pathogenesis of chronic neuropathic pain ([@B56]). Furthermore, this speculation was also demonstrated by a large number of researchers. For instance, Liu et al. constructed a mouse model of spared nerve injury-induced neuropathic pain and found, by microarray technology, that there were 22,213 abnormally expressed lncRNAs, which might be involved in the activities of cytokines (IL-17A and IL-17F) and chemokines (CCL-2, CCL-5, and CCL-7), in the spinal cord, suggesting that differentially expressed lncRNAs played a pivotal role in the progression of neuropathic pain ([@B59]). Additionally, Jiang et al. identified 511 differentially expressed (\>2-fold change) lncRNAs (366 up-regulated and 145 down-regulated) in the spinal cord of mice following spinal nerve ligation-induced neuropathic pain, and these lncRNAs might be related to Toll-like receptor signaling, cytokine--cytokine receptor interaction, and peroxisome proliferator-activated receptor signaling pathways, which indicated that abnormally expressed lncRNAs might be implicated in the pathogenesis of chronic neuropathic pain ([@B42]). With the deepening of lncRNA research, scientists are no longer limited to the study of lncRNA expression profiles of chronic neuropathic pain, and they have begun to specifically explore the biological function of these differentially expressed lncRNAs in chronic neuropathic pain ([@B106]). Thus, the amassing literature referring to lncRNAs in chronic neuropathic pain is presented in detail in [Table 3](#T3){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}.

###### 

Comprehensive analysis of aberrant lncRNA expression profiles in chronic neuropathic-related conditions.

  **lncRNAs**                                                                     **Expression levels**   **Localization of lncRNAs expression**                                        **Samples**                                              **Potential regulatory mechanism of dysregulated lncRNAs**                                                                                                                                                                                                                                                                        **References**
  ------------------------------------------------------------------------------- ----------------------- ----------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  BC168687                                                                        Up-regulated            DRG neurons                                                                   Streptozotocin-induced diabetic rats                     lncRNA BC168687 may participate in the pathogenesis of diabetic neuropathic pain mediated by P2 × 7 receptor.                                                                                                                                                                                                                     [@B58]
  CCAT1 (Colon cancer-associated transcript-1)                                    Down-regulated          DRG neurons, spinal dorsal horn, hippocampus and anterior cingulated cortex   Bilateral sciatic nerve CCI rats                         lncRNA CCAT1 overexpression could alleviate the pain thresholds and promote the expression of serum and glucocorticoid regulated protein kinase 3 (SGK3) through sponging miR-155.                                                                                                                                                [@B19]
  DGCR5 (DiGeorge syndrome critical region gene 5)                                Down-regulated          DRG neurons                                                                   CCI rats                                                 DGCR5 overexpression was able to alleviate neuropathic pain development including mechanical and thermal hyperalgesia through sponging miR-330-3p and regulating PDCD4 in CCI rat models.                                                                                                                                         [@B69]
  KCNA2-AS (Potassium voltage-gated channel subfamily A member 2 antisense RNA)   Up-regulated            DRG neurons                                                                   Rat, mouse, monkey and human                             Overexpression of KCNA2-AS down-regulated Kcna2, reduced total voltage-gated potassium current, increased excitability in DRG neurons, and produced neuropathic pain symptoms, but blocking KCNA2-AS reversed nerve injury-induced down-regulation of DRG Kcna2 and attenuated development and maintenance of neuropathic pain.   [@B56]
  LINC00657                                                                       Up-regulated            DRG neurons                                                                   CCI rats                                                 LINC00657 suppressed neuropathic pain-related symptoms, such as mechanical and thermal hyperalgesia, by modulating miR-136/ZEB1 axis.                                                                                                                                                                                             [@B89]
  MALAT1 (metastasis-associated lung adenocarcinoma transcript 1)                 Down-regulated          DRG neurons                                                                   CCI rats                                                 Neuropathic pain behaviors such as mechanical and thermal hyperalgesia were reduced by the inhibition of MALAT1, while the loss of MALAT1 was able to depress the neuroinflammation process via the inhibition of COX-2, interleukin-1β, and interleukin-6 accompanied by miR-206/ZEB2 axis.                                      [@B16]
  MRAK009713                                                                      Up-regulated            DRG neurons                                                                   CCI rats                                                 MRAK009713 is a novel positive regulator of neuropathic pain in rats through regulating the expression and function of the P2 × 3 receptor.                                                                                                                                                                                       [@B52]
  NEAT1 (Nuclear paraspeckle assembly transcript 1)                               Up-regulated            Spinal cord                                                                   CCI rats                                                 NEAT1 contributes to neuropathic pain development through targeting miR-381/HMGB1 axis in CCI rat models.                                                                                                                                                                                                                         [@B107]
  NON-RATT021972                                                                  Up-regulated            DRG neurons                                                                   Type 2 diabetes mellitus rats                            NON-RATT021972 siRNA treatment suppressed the up-regulated expression and activation of the P2 × 3 receptor and reduced the hyperalgesia potentiated by the pro-inflammatory cytokine TNF-α in Type 2 diabetes mellitus rats.                                                                                                     [@B70]
  PKIA-AS1 (PKIA antisense RNA 1)                                                 Up-regulated            Spinal cord                                                                   Spinal nerve ligation model rats                         Overexpression of PKIA-AS1 was sufficient to induce neuropathic pain-like symptoms in uninjured rats by directly regulating the expression and function of CDK6, which is essential for the initiation and maintenance of neuroinflammation and neuropathic pain.                                                                 [@B35]
  SCN9A NAT (SCN9A natural antisense transcript)                                  Down-regulated          DRG neurons                                                                   Painful diabetic rats                                    SCN9A NAT correlates with the emergence of pain-related behaviors characteristic of painful diabetic neuropathy.                                                                                                                                                                                                                  [@B55]
  T-UCRs (Transcribed ultraconserved regions)                                     Up-regulated            Spinal cord                                                                   Spinal nerve ligation-induced neuropathic pain in mice   T-UCR involved in the pathogenesis of neuropathic pain.                                                                                                                                                                                                                                                                           [@B43]
  uc.48+                                                                          Up-regulated            DRG neurons                                                                   Diabetic rats                                            The siRNA treatment of lncRNA uc.48+ may alleviate the diabetic neuropathic pain by inhibiting the excitatory transmission mediated by the P2 × 3 receptor in DRG.                                                                                                                                                                [@B101]
  XIST (X inactive specific transcript)                                           Up-regulated            Spinal cord                                                                   CCI rats                                                 XIST accelerates neuropathic pain progression through regulation of miR-137/TNFAIP1, miR-154/STAT3, or miR-150/ZEB1 axis in CCI rat models.                                                                                                                                                                                       [@B103]; [@B110]; [@B113]

![Aberrant lncRNA expression and their downstream molecular pathways in chronic neuropathic pain. The red arrow represented an up-regulated trend of lncRNAs, and the green arrow represented a down-regulated trend of lncRNAs.](fnins-13-01097-g002){#F2}

It should be pointed out that all the current biological functions related to lncRNAs in chronic neuropathic pain are based on cellular or animal models, and research on the human body can be limited only to their expression levels, but not their biological functions ([@B49]). The major reason is that chronic neuropathic pain is usually prone to irreversible damage in the human body, which is difficult for us to control ([@B25]). Hence, animal models of chronic neuropathic pain can be mainly grouped into four categories, including nerve injury models \[such as spinal cord injury, excitotoxins, spinal hemi-section, thalamic syndrome, sciatic nerve chronic constriction injury (CCI), spinal nerve ligation, spared nerve injury, sciatic inflammatory neuritis, etc.\], drug-induced chronic neuropathic pain models (such as anti-cancer-agent-induced neuropathy, vincristine-induced neuropathic pain, cisplatin-induced neuropathic pain, etc.), disease-induced neuropathy models (such as diabetes-induced neuropathy, the post-herpetic neuralgia model, human-immunodeficiency-virus-induced neuropathy, etc.), and miscellaneous models \[such as chronic ethanol consumption/withdrawal-induced neuropathy, pyridoxine (vitamin B6)-induced neuropathy, inherited-induced neuropathies, etc.\] ([@B49]). Based on these models, whether the roles of lncRNAs in chronic neuropathic pain can be well reflected in the human body still needs to be further explored.

Conclusion and Future Directions {#S4}
================================

Chronic neuropathic pain is one of the most challenging and refractory neurological diseases in a great number of patients ([@B25]). In the clinic, chronic neuropathic pain patients are often characterized by symptoms of spasticity, muscle weakness, dysesthesia, spontaneous pain, allodynia, hyperalgesia, poor proprioception, and so on ([@B26]). Currently, in response to these symptoms of chronic neuropathic pain, there are still no clinically effective drugs for their treatment ([@B27]). Previous studies have precisely revealed that the available analgesics, such as non-steroidal anti-inflammatory drugs and opioids, which could effectively improve the clinical signs or symptoms of nociceptive pain, did not produce an adequate effect on chronic neuropathic pain patients ([@B98]). Emerging lines of evidence have also uncovered that, despite a mass of pharmacological studies performed in chronic neuropathic pain, these newly developed treatment strategies, including pharmacological, non-pharmacological, and interventional methods, remain unable to adequately alleviate the patients' pain or reduce the pain only to a range that the patients can tolerate ([@B37]). Moreover, on the other hand, epidemiological surveys have reported that the prevalence of chronic neuropathic pain in the gross population is approximately 7--10% around the world ([@B115]; [@B96]). Therefore, chronic neuropathic pain represents a worldwide challenging issue that is a socio-economic burden not only for patients and caregivers but also for the healthcare system ([@B5]). Currently, an increasing number of clinicians believe that patients with chronic neuropathic pain have not been treated well because the pathogenesis of the disease is not completely understood ([@B98]). In-depth studies of the pathogenesis of chronic neuropathic pain may provide a solid theoretical basis for the development of new drugs or agents. lncRNAs, belonging to a family of RNAs characterized as transcripts more than 200 nucleotides in length, were discovered to participate in the cellular and molecular pathological processes of multiple nervous system diseases, including chronic neuropathic pain, by regulating the expression of neuronal-function-related genes ([@B75]; [@B106]). Hence, many researchers have turned their attention to the study of lncRNAs, with the thought that unveiling the underlying mechanism of how lncRNAs are involved in the occurrence, development and progression of chronic neuropathic pain may offer novel avenues to prevent and treat this refractory disease ([@B77]).

In recent years, small-molecule targeted therapies using miRNAs or lncRNAs have been carried out in many disease areas. These molecules attracted so much attention due to their biology functions in regulating protein-coding genes at different levels, including epigenetic level, transcription level, post-transcriptional level, etc. In addition, their expressions not only have temporal and spatial specificity, but also cell and tissue specificity. Thus, these biological characteristics enable drug developers to find more accurate targets when developing new drugs or agents. Nonetheless, it is undeniable that there are still many challenges in the application of small molecules in the treatment of chronic neuropathic pain, for example, the transformation between experiment research and clinical application. Given that chronic neuropathic pain can cause irreversible damage to the human body, almost all models for chronic neuropathic pain research are based on cell or animal experiments. However, there are some differences between *in vitro* experiments and *in vivo* experiments, and these differences are unpredictable. Therefore, how the results obtained by small-molecule targeted therapy in *in vitro* experiments can be transformed and applied to human body is still a big problem.
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